BANK VONTOBEL/CALL/GILEAD SCIENCES/76/0.05/20.12.24 | Market Closed - Swiss Exchange 08:50:00 14/06/2024 pm IST | ||
| 0.062 CHF | +19.23% |
|
| 1 month | -39.22% | ||
| 3 months | -77.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 0.062 | +19.23% |
Delayed Quote Swiss Exchange
Last update June 14, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WGIA3V | |
| ISIN | CH1274773139 |
| Date issued | 07/07/2023 |
| Strike | 76 $ |
| Maturity | 20/12/2024 (187 Days) |
| Parity | 20 : 1 |
| Emission price | 0.46 CHF |
| Emission volume | N/A |
| Settlement | fisico |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.71 CHF |
|---|---|
| Lowest since issue | 0.052 CHF |
| Spread | 0.01 CHF |
| Spread % | 13.89% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.06
USD
Average target price
82.7
USD
Spread / Average Target
+27.11%
- Stock Market
- Warrants
- WGIA3V Warrant
